Hope House, an organization working to improve the quality of life for Memphians impacted by HIV, has received a $75,000 grant from Gilead Sciences Inc., marking the largest single corporate grant the organization has received.

2. Hope House Awarded $75K Corporate Grant - Wednesday, June 27, 2018

Hope House, an organization working to improve the quality of life for Memphians impacted by HIV, has received a $75,000 grant from Gilead Sciences Inc., marking the largest single corporate grant the organization has received.

3. Jury: Gilead Owes Merck $200M in Damages Over Drug Patents - Monday, March 28, 2016

The federal jury in a patent trial has ordered drugmaker Gilead Sciences to pay Merck $200 million in damages for infringing on patents for hepatitis C drugs.

The award is far below the damages Merck sought, but the trial moves to a new phase Wednesday. The jury, in San Jose, California, then will decide whether Merck & Co. is due royalties on sales of Gilead's hepatitis C drugs, Harvoni and Sovaldi.

4. FDA Drug Approvals Reached 18-Year High in 2014 - Monday, January 5, 2015

WASHINGTON (AP) – The Food and Drug Administration approved 41 first-of-a-kind drugs in 2014, including a record number of medicines for rare diseases, pushing the agency's annual tally of drug approvals to its highest level in 18 years.

5. UTHSC Awarded $50,000 for Hepatitis C Education - Wednesday, October 1, 2014

Patricia Matthews-Juarez, co-director of the Research Center on Health Disparities, Equity, and the Exposome and professor in the Department of Preventive Medicine at the University of Tennessee Health Science Center, has received a $50,000 grant from Gilead Sciences Inc. to conduct a provider education and community awareness program about the Hepatitis C virus in the African-American community.

6. $1,000-a-Pill Sovaldi Jolts US Health Care System - Wednesday, June 18, 2014

WASHINGTON (AP) – Your money or your life?

Sovaldi, a new pill for hepatitis C, cures the liver-wasting disease in 9 of 10 patients, but treatment can cost more than $90,000.

Leading medical societies recommend the drug as a first-line treatment, and patients are clamoring for it. But insurance companies and state Medicaid programs are gagging on the price. In Oregon, officials propose to limit how many low-income patients can get Sovaldi.

7. Merck to Pay $3.85 Billion for Hepatitis C Drug Developer - Tuesday, June 10, 2014

TRENTON, N.J. (AP) – Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck's experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

8. New Drug Approvals From FDA Declined in 2013 - Friday, January 3, 2014

WASHINGTON (AP) – The Food and Drug Administration approved 27 first-of-a-kind drugs in 2013, down from 39 new medications in 2012, which was a 15-year high.

Despite the decline, FDA officials say the tally of innovative medications approved last year is in line with the historical trend. On average, the FDA has approved 28 first-of-a-kind drugs annually over the past five years.

9. Drug Stops HIV Among Hetero Couples, Not Just Gays - Thursday, July 14, 2011

ATLANTA (AP) – An AIDS drug already shown to help prevent spread of the virus in gay men also works for heterosexual men and women, two studies in Africa found. Experts called it a breakthrough for the continent that has suffered most from AIDS.

10. Swine Flu Casts Shadow Over Economy - Tuesday, April 28, 2009

LONDON (AP) - Uncertainty over the swine flu outbreak cast a shadow over the struggling global economy Monday, raising fears that that the spread of the virus could harm trade and tourism and undermine businesses just as they begin to rally.

11. Glaxo and Pfizer Create New HIV Drug Company - Monday, April 20, 2009

TRENTON, N.J. (AP) - Pharmaceutical giants GlaxoSmithKline PLC and Pfizer Inc. will pool resources to create a new company to develop and sell HIV medicines, leveraging a small investment into the No. 2 market position.